HK81397A - Pharmaceutical compositions containing benzenesulphonamides - Google Patents

Pharmaceutical compositions containing benzenesulphonamides Download PDF

Info

Publication number
HK81397A
HK81397A HK81397A HK81397A HK81397A HK 81397 A HK81397 A HK 81397A HK 81397 A HK81397 A HK 81397A HK 81397 A HK81397 A HK 81397A HK 81397 A HK81397 A HK 81397A
Authority
HK
Hong Kong
Prior art keywords
physical form
benzenesulphonamides
pharmaceutical compositions
compositions containing
hoxybenzoyl
Prior art date
Application number
HK81397A
Other languages
English (en)
Inventor
Joseph Holohan James
John Edwards Ieuan
Joseph Timko Robert
Clements Arlene
John Bradway Randy
Original Assignee
Astrazeneca Uk Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26298105&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK81397(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB909027014A external-priority patent/GB9027014D0/en
Priority claimed from GB919115107A external-priority patent/GB9115107D0/en
Application filed by Astrazeneca Uk Limited filed Critical Astrazeneca Uk Limited
Publication of HK81397A publication Critical patent/HK81397A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/40—Nitrogen atoms, not forming part of a nitro radical, e.g. isatin semicarbazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Inorganic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
HK81397A 1990-12-12 1997-06-19 Pharmaceutical compositions containing benzenesulphonamides HK81397A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB909027014A GB9027014D0 (en) 1990-12-12 1990-12-12 Pharmaceutical agents
GB919115107A GB9115107D0 (en) 1991-07-12 1991-07-12 Pharmaceutical agents

Publications (1)

Publication Number Publication Date
HK81397A true HK81397A (en) 1997-06-27

Family

ID=26298105

Family Applications (2)

Application Number Title Priority Date Filing Date
HK81397A HK81397A (en) 1990-12-12 1997-06-19 Pharmaceutical compositions containing benzenesulphonamides
HK81597A HK81597A (en) 1990-12-12 1997-06-19 Physical forms of benzenesulphonamides

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK81597A HK81597A (en) 1990-12-12 1997-06-19 Physical forms of benzenesulphonamides

Country Status (30)

Country Link
US (6) US5319097A (enExample)
EP (1) EP0490648B1 (enExample)
JP (1) JP2585495B2 (enExample)
KR (2) KR0183027B1 (enExample)
CN (2) CN1043405C (enExample)
AP (1) AP285A (enExample)
AT (1) ATE131048T1 (enExample)
AU (1) AU656157B2 (enExample)
BE (1) BE1004229A5 (enExample)
CA (2) CA2319308C (enExample)
CZ (1) CZ283181B6 (enExample)
DE (2) DE69115229T2 (enExample)
DK (1) DK0490648T3 (enExample)
ES (1) ES2079589T3 (enExample)
FI (1) FI101193B (enExample)
FR (1) FR2670488B1 (enExample)
GB (2) GB2280606B (enExample)
GR (1) GR3018318T3 (enExample)
HK (2) HK81397A (enExample)
HU (2) HU213211B (enExample)
IE (1) IE75348B1 (enExample)
IL (1) IL100091A (enExample)
IT (1) IT1256282B (enExample)
MX (1) MX9102473A (enExample)
MY (1) MY106315A (enExample)
NZ (1) NZ240939A (enExample)
PH (1) PH30928A (enExample)
RU (1) RU2106140C1 (enExample)
SK (2) SK279813B6 (enExample)
TW (1) TW276181B (enExample)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL100091A (en) * 1990-12-12 1998-08-16 Zeneca Ltd Pharmaceutical compositions containing a physical form of n-[4-[5-(cyclopentyloxycarbonyl)amino-1-methyl indol-3-yl-methyl]-2-methylbenzenesulpho-namide and process for their preparation
GB9119001D0 (en) * 1991-09-05 1991-10-23 Ici Plc Pharmaceutical agents
GR1001368B (el) * 1992-10-08 1993-10-29 Ici Plc Φαρμακευτικοί φορείς.
DE4235133A1 (de) * 1992-10-19 1994-04-21 Bayer Ag Kristallines (R)-(-)-2-Cycloheptyl-N-methylsulfonyl-[4-(2-chinolinyl-methoxy)-phenyl]-acetamid
DE9410461U1 (de) * 1994-07-01 1994-09-22 Merck Patent Gmbh, 64293 Darmstadt Mittel für die Röntgenfluoreszenzanalyse
US6279736B1 (en) 1995-04-19 2001-08-28 Capitol Specialty Plastics, Inc. Barrier pack having an absorbing agent applied to the interior of the pack
IN182496B (enExample) * 1996-02-20 1999-04-17 Reddy Research Foundation
US6630496B1 (en) 1996-08-26 2003-10-07 Genetics Institute Llc Inhibitors of phospholipase enzymes
USRE43932E1 (en) 1997-07-18 2013-01-15 Novartis Ag Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use
GB9723985D0 (en) * 1997-11-14 1998-01-14 Zeneca Ltd Pharmaceutical compositions
GB9726735D0 (en) * 1997-12-18 1998-02-18 Zeneca Ltd Pharmaceutical compositions
US6828344B1 (en) 1998-02-25 2004-12-07 Genetics Institute, Llc Inhibitors of phospholipase enzymes
US6916841B2 (en) * 1998-02-25 2005-07-12 Genetics Institute, Llc Inhibitors of phospholipase enzymes
US6500853B1 (en) 1998-02-28 2002-12-31 Genetics Institute, Llc Inhibitors of phospholipase enzymes
US6224907B1 (en) 1998-03-06 2001-05-01 Alza Corporation Anti-asthma therapy
KR100283682B1 (ko) * 1998-07-14 2001-03-02 조정래 열풍건조장치
US6253463B1 (en) 1999-04-26 2001-07-03 Niro A/S Method of spray drying
IN191496B (enExample) 1999-07-30 2003-12-06 Ranbaxy Lab Ltd
WO2001021211A2 (en) * 1999-09-20 2001-03-29 Alza Corporation Process for lessening polymorphic conversion of a drug
DE10006139A1 (de) * 2000-02-11 2001-08-16 Merck Patent Gmbh Indol-3-yl-Derivate
IL139243A0 (en) * 2000-10-24 2001-11-25 Internat Specialty Products Is Ethanolate of zafirlukast, process for manufacture and pharmaceutical compositions thereof
IL140096A0 (en) * 2000-12-05 2002-02-10 Internat Specialty Products Is Process for preparation of zafirlukast
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
RU2756946C2 (ru) 2001-01-26 2021-10-07 Мерк Шарп И Доум Корп. Применение замещенных азетидинонов для лечения ситостеролемии
US20060287254A1 (en) * 2001-01-26 2006-12-21 Schering Corporation Use of substituted azetidinone compounds for the treatment of sitosterolemia
AU2002247019C1 (en) * 2001-01-26 2017-05-11 Organon Llc Combinations of peroxisome proliferator-activated receptor (PPAR) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
CA2453182A1 (en) * 2001-07-10 2003-01-23 Meredith L. Greene Crystalline thiazine oxazolidinones
EP1419151B1 (en) * 2001-08-15 2014-02-26 Pharmacia & Upjohn Company LLC Chrystals including a malic acid salt of n-[2-(diethylamino)ethyl] -5-[(5-fluoro-1,2-dihydro-2-oxo-3h-indole-3-ylidene)methyl] -2,4-dimethyl-1h-pyrrole-3-carboxamide, processes for its preparation and compositions thereof
DE60216300T2 (de) * 2001-09-21 2007-06-28 Schering Corp. Behandlung von xanthom mittels azetidinon-derivate als hemmer der sterol absorption
US7053080B2 (en) * 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
AR040588A1 (es) * 2002-07-26 2005-04-13 Schering Corp Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
CA2504878A1 (en) 2002-11-06 2004-05-27 Schering Corporation Cholesterol absorption inhibitors for the treatment of demyelination
US7459442B2 (en) * 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
EP1601668B1 (en) * 2003-03-07 2008-08-27 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
MXPA05009502A (es) 2003-03-07 2005-10-18 Schering Corp Compuestos de azetidinona sustituidos, formulaciones y usos de los mismos para el tratamiento de hipercolesterolemia.
MXPA05009501A (es) * 2003-03-07 2005-10-18 Schering Corp Compuestos de azetidinona sustituidos, formulaciones y usos de los mismos para el tratamiento de hipercolesterolemia.
US20050026882A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease
US20090317476A1 (en) * 2003-07-31 2009-12-24 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease
US20050113410A1 (en) * 2003-11-03 2005-05-26 Mark Tawa Pharmaceutical salts of zafirlukast
MY142017A (en) * 2004-03-19 2010-08-16 Nestec Sa Composition comprising all essential nutrients of a fruit or a plant material with increased stability and bioavailability and process of forming the same
ITMI20041032A1 (it) * 2004-05-24 2004-08-24 Neuroscienze S C A R L Compositi farmaceutici
JP2008531721A (ja) * 2005-03-03 2008-08-14 エラン・ファルマ・インターナショナル・リミテッド 複素環式アミド誘導体のナノ粒子状組成物
US20070197467A1 (en) * 2006-02-06 2007-08-23 Srinivasulu Rangineni Zafirlukast compositions
US20090012146A1 (en) * 2007-07-02 2009-01-08 Giridhar Reddy Buggana Solubility-enhanced pharmaceutical compositions comprising zafirlukast
JP2010535234A (ja) * 2007-07-30 2010-11-18 オースペックス・ファーマシューティカルズ・インコーポレイテッド 置換インドール
US20090149662A1 (en) * 2007-12-05 2009-06-11 Raghupathi Reddy Anumula Processes for preparing zafirlukast
WO2014012954A1 (en) 2012-07-18 2014-01-23 Takeda Gmbh Treatment of partly controlled or uncontrolled severe asthma
CA2936332A1 (en) 2014-01-22 2015-07-30 Takeda Gmbh Treatment of partly controlled or uncontrolled severe asthma with a pde4 inhibitor (and in combination with a leukotriene modifier)
PT109030B (pt) 2015-12-15 2019-09-25 Hovione Farmaciência, S.A. Preparação de partículas inaláveis de zafirlucaste
EP3585809B1 (en) 2017-01-30 2025-07-02 Western New England University Zafirlukast for use in treating thrombosis
US10752585B2 (en) 2017-12-28 2020-08-25 Council Of Scientific & Industrial Research Process for the preparation of Zafirlukast and analogs thereof
US12403122B2 (en) 2021-05-19 2025-09-02 Quercis Pharma AG Method for treating amyotrophic lateral sclerosis using quercetin-containing compositions
US20250275936A1 (en) 2022-05-06 2025-09-04 Quercis Pharma AG Method for treating cancers and neurological diseases using quercetin-containing compositions

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607294D0 (en) * 1985-04-17 1986-04-30 Ici America Inc Heterocyclic amide derivatives
IL100091A (en) * 1990-12-12 1998-08-16 Zeneca Ltd Pharmaceutical compositions containing a physical form of n-[4-[5-(cyclopentyloxycarbonyl)amino-1-methyl indol-3-yl-methyl]-2-methylbenzenesulpho-namide and process for their preparation
GB9027018D0 (en) * 1990-12-12 1991-01-30 Ici Plc Heterocyclic compounds

Also Published As

Publication number Publication date
ITMI913324A1 (it) 1993-06-11
TW276181B (enExample) 1996-05-21
MY106315A (en) 1995-04-29
GB9418154D0 (en) 1994-10-26
PH30928A (en) 1997-12-23
CS375691A3 (en) 1992-06-17
DE4140858A1 (de) 1992-06-17
JP2585495B2 (ja) 1997-02-26
GB2251791A (en) 1992-07-22
US5612367A (en) 1997-03-18
HUT61281A (en) 1992-12-28
GR3018318T3 (en) 1996-03-31
DK0490648T3 (da) 1996-05-06
US5482963A (en) 1996-01-09
US5993859A (en) 1999-11-30
FI101193B1 (fi) 1998-05-15
CA2319308C (en) 2001-08-21
ITMI913324A0 (it) 1991-12-11
IL100091A0 (en) 1992-08-18
IE75348B1 (en) 1997-08-27
SK279813B6 (sk) 1999-04-13
GB9126354D0 (en) 1992-02-12
CA2056066C (en) 2002-04-02
CA2056066A1 (en) 1992-06-13
IE914310A1 (en) 1992-06-17
AP285A (en) 1993-09-23
JPH04266824A (ja) 1992-09-22
CA2319308A1 (en) 1992-06-13
EP0490648A1 (en) 1992-06-17
GB2280606B (en) 1995-05-17
DE69115229T2 (de) 1996-05-09
CN1243827A (zh) 2000-02-09
FI915826L (fi) 1992-03-31
ATE131048T1 (de) 1995-12-15
FI915826A0 (fi) 1991-12-11
KR920011493A (ko) 1992-07-24
AU8899491A (en) 1992-06-18
HU913865D0 (en) 1992-02-28
FI101193B (fi) 1998-05-15
MX9102473A (es) 1992-06-01
US5504216A (en) 1996-04-02
EP0490648B1 (en) 1995-12-06
CN1043405C (zh) 1999-05-19
FR2670488B1 (fr) 1994-01-28
SK279814B6 (sk) 1999-04-13
AU656157B2 (en) 1995-01-27
KR0183027B1 (ko) 1999-05-01
IT1256282B (it) 1995-11-29
CN1062291A (zh) 1992-07-01
ES2079589T3 (es) 1996-01-16
RU2106140C1 (ru) 1998-03-10
GB2280606A (en) 1995-02-08
HU211126A9 (en) 1995-10-30
NZ240939A (en) 1994-05-26
IL100091A (en) 1998-08-16
GB2251791B (en) 1995-05-17
AP9100340A0 (en) 1992-01-31
FR2670488A1 (fr) 1992-06-19
KR970005014A (ko) 1997-01-29
US6143775A (en) 2000-11-07
CN1105705C (zh) 2003-04-16
US5319097A (en) 1994-06-07
BE1004229A5 (fr) 1992-10-13
HU213211B (en) 1997-03-28
DE69115229D1 (de) 1996-01-18
HK81597A (en) 1997-06-27
CZ283181B6 (cs) 1998-01-14
KR100207802B1 (ko) 1999-07-15

Similar Documents

Publication Publication Date Title
HK81397A (en) Pharmaceutical compositions containing benzenesulphonamides
ZA975866B (en) Novel heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases.
WO2001087329A8 (en) Liquid pharmaceutical composition containing an erythropoietin derivate
HUP0303398A3 (en) 1,2-dihydropyridine compounds, process for preparation of the same and use thereof and pharmaceutical compositions containing the same
HU0301171D0 (en) Antifungal active ingredients, pharmaceutical compositions containing the same and process for their preparation
AU2003215524A1 (en) Pharmaceutical compositions comprising mannose binding lectin
BG104877A (en) N-substituted anminotetralins as ligands for the neuropeptide y y5 receptor useful in the treatment of obesity and other disorders
HUP9603237A2 (hu) (R)-(-)-2-{N-[4-(1,1-dioxido-3-oxo-2,3-dihidro-benzizotiazol-2-il)-butil]-amino-metil}-kromán kristályos hidrokloridja, eljárás előállítására és a vegyületeket tartalmazó gyógyszerkészítmények
ZA200300712B (en) Pharmaceutical compositions for the treatment of mucositis, stomatitis and Behcet's syndrome.
NO902800D0 (no) Fremgangsmaate for fremstilling av 11beta-aryl-4-oestrener.
HUP0000960A3 (en) Spray-dried paroxetine hydrochloride, process for it's preparation,use of the compound and pharmaceutical compositions containing the same
HUP0301116A3 (en) Novel form of (r)-n-[5-methyl-8-(4-methylpiperazin-1-yl)-1,2,3,4-tetrahydro-2-naphthyl]-4-morpholinobenzamide, process for its preparation and pharmaceutical composition containing it
WO2003020963A3 (en) Proteins in type 2 diabetes
CA2340734A1 (en) Optically active pyridyl-4h-1,2,4-oxadiazine derivative and its use in the treatment of vascular diseases
BG105204A (en) Salts of paroxetine
HUP9702480A3 (en) New polymorphous form of doxazosin-mesylate (form. i.), process for it's preparation and pharmaceutical compositions containing the same
IL109866A0 (en) Crystalline 3-(4-hexyloxy-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyridine (+) l-hydrogentartrate, its preparation and pharmaceutical compositions containing it
IL61580A (en) Quinoline derivatives,the preparation of 1-(8-quinolyl)-2-pyrrolidinone and pharmaceutical compositions containing it
HUP9702479A3 (en) New polymorphous form of doxazosin-mesylate (form ii.), process for it's preparation and pharmaceutical compositions containing the same
EP0386920A3 (en) 2-hydroxy-3-thienyloxypropylamino derivatives
HUP9900401A3 (en) Novel substituted n-methyl-n-(4-(4-(1h-benzimidazol-2-yl)[1,4]diazepan-1-yl)-2-(aryl)butyl)benzamides useful for the treatment of allergic diseases, pharmaceutical compositions containing them and their use
AU610456B2 (en) 4-ethyl-3-(substituted phenyl)-1-(3-trifluoromethylphenyl) -2-pyrrolidinone derivatives, processes for the preparation and use thereof, herbicidal compositions containing them
HUP0000812A2 (hu) Myelin bázikus fehérje peptid-fragmentumai az azokat tartalmazó gyógyszerkészítmények és felhasználásuk a sclerosis multiplex kezelésére
WO2003040119A8 (fr) Inhibiteurs de l'angiogenese
WO1993018059A3 (en) L-thiazolidine-4-carboxylic acid derivative, processes for the preparation thereof and the use thereof in therapy

Legal Events

Date Code Title Description
PF Patent in force
PE Patent expired

Effective date: 20111210